Erica Gregonis, MD
Pulmonary Disease · Richmond, KYNPI 1326242991
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $321,538 of the $389,657 with a category attached, or 82.5%. GSK accounts for 98.1% of it on its own, with 30 other manufacturers making up the rest. Among pulmonary disease clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 524 payments — averaging $743.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$382K
- Viiv Healthcare Company$3K
- Intuitive Surgical$754
- AstraZeneca$514
- Grifols USA, LLC$390
- Verona Pharma, Inc.$330
- plus $2K from 25 others
What the payments were for
- Consulting fees$40,78810%
- Speaking & faculty fees$321,53883%
- Travel & lodging$15,6404%
- Food & beverage$11,5633%
- Education$970%
- Gifts$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 363 | $382,303 |
| Viiv Healthcare Company | 2 | $3,493 |
| Intuitive Surgical | 3 | $754 |
| AstraZeneca | 31 | $514 |
| Grifols USA, LLC | 29 | $390 |
| Verona Pharma, Inc. | 9 | $330 |
| Boehringer Ingelheim | 14 | $300 |
| Pulmonx Corporation | 2 | $201 |
| Sanofi | 8 | $177 |
| Insmed, Inc. | 8 | $161 |
| Philips North America LLC | 8 | $138 |
| Genentech USA, Inc. | 6 | $123 |
| Amgen | 5 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Regeneron Healthcare Solutions, Inc. | 3 | $80 |
| Mallinckrodt Enterprises LLC | 3 | $67 |
| Actelion Pharmaceuticals US, Inc. | 3 | $65 |
| Mylan Specialty L.p. | 3 | $44 |
| Mallinckrodt Hospital Products Inc. | 2 | $42 |
| AbbVie | 2 | $41 |
| United Therapeutics Corporation | 2 | $40 |
| Circassia Inc. | 2 | $36 |
| Novartis | 2 | $27 |
| Breathe Technologies, Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $23 |
| Viatris Specialty LLC | 1 | $21 |
| Merck | 1 | $19 |
| Inogen, Inc. | 3 | $18 |
| Fisher & Paykel Healthcare Inc | 1 | $14 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$118,798
- AREXVY$113,896
- NUCALA$77,471
- ANORO ELLIPTA$8,575
- ANORO$4,733
- Da Vinci Surgical System$660
- Pulmonx Endobronchial Valve EBV$175
- Ohtuvayre$121
How this compares
$389,657 in reported general payments places this provider in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $163,276 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $115,043 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $27,324 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $13,123 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,507 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,231 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 138 | $3,727 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,643 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 11 | $3,196 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $1,561 |
| Montelukast Sodium | 38 | $230 |
| Azithromycin | 15 | $104 |
| Pantoprazole Sodium | 18 | $99 |
| Omeprazole | 21 | $72 |
| Prednisone | 16 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $390 | $163,27613 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $382,303 | $122,470137 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $514 | $32,83154 claims |
| Boehringer IngelheimStiolto Respimat | $300 | $13,12320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Richmond
- Muhammad IqbalRichmond$9K
- John McConnellLouisville$864K
- Firas KouraGeorgetown$350K
- Harold HallerLouisville$340K
- Steven KoenigMorehead$242K
- Samantha BaahLouisville$226K
- Sandra SchuldheiszSomerset$225K
- Karim El-KershLouisville$180K
- Dennis DohertyLexington$103K
- Josephine MeiLouisville$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.